The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...

Downtown Rochester has gone through many changes over the years from being known as an industrial hub to more of an urban ...

Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Bausch + Lomb (NYSE ...

Regardless of whether it's toys, cars, or high-tech gadgets, many U.S. companies have outsourced what they manufacture to ...

Wells Fargo & Company reiterated their equal weight rating on shares of Bausch + Lomb (NYSE:BLCO – Free Report) in a report issued on Friday morning, MarketBeat.com reports. They currently have a $15.

Raymond James Financial Inc. bought a new stake in Bausch + Lomb Co. (NYSE:BLCO – Free Report) during the fourth quarter, ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of ...

Eye health company Bausch + Lomb has issued a voluntary recall of a series of intraocular lenses, according to a March 27 ...

Bausch + Lomb (NYSE:BLCO) stock falls as the company's voluntary recall of enVista lenses leads to a downgrade at Wells Fargo ...